<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691011</url>
  </required_header>
  <id_info>
    <org_study_id>2020-50</org_study_id>
    <nct_id>NCT04691011</nct_id>
  </id_info>
  <brief_title>New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>IRM-SLA</acronym>
  <official_title>New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative&#xD;
      disorder. There is no treatment that significantly slows progression. Our project aims to&#xD;
      find new biomarkers in MRI at three levels: cerebral, medullary and muscular. These markers&#xD;
      could allow an earlier diagnosis of the disease by showing more specific lesions of ALS and&#xD;
      to quantify these lesions to measure the progression of the disease. This study will use&#xD;
      advanced Magnetic Resonance Imaging (MRI) techniques High field (3T) and very high field (7T)&#xD;
      MRI. Results from neurological and electrophysiological tests will be compared to the MRI.&#xD;
      Subjects will be recruited from ALS center of Marseille, France. MRI will be done on ALS&#xD;
      patients at baseline, at 3 month and at 6 month intervals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>3 groups :&#xD;
muscle&#xD;
brain&#xD;
spinal cord</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression using MRI</measure>
    <time_frame>Change from Baseline and at Month 6</time_frame>
    <description>Muscular, brain and spinal cord MRI (brain sodium concentration, muscular volume of members, measure of transversal area for spinal cord)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Link between MRI and clinical scales</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>ALSFRS score, MRC score, ECAS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Link between MRI and MUNIX</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>For muscle, brain and spinal cord group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations of metabolic and funtional brain</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Multiparametric MRI (diffusion parameters, myelin parameters, quantification of fat-infiltration and oedema)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Muscle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spinal cord</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brain</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Muscular MRI</intervention_name>
    <description>MRI (1.5T)</description>
    <arm_group_label>Brain</arm_group_label>
    <arm_group_label>Muscle</arm_group_label>
    <arm_group_label>Spinal cord</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrophysiological exam</intervention_name>
    <description>MUNIX</description>
    <arm_group_label>Brain</arm_group_label>
    <arm_group_label>Muscle</arm_group_label>
    <arm_group_label>Spinal cord</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain MRI</intervention_name>
    <description>MRI (7T)</description>
    <arm_group_label>Brain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spinal cord MRI</intervention_name>
    <description>7T and 3T MRI</description>
    <arm_group_label>Spinal cord</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients will be adults with a diagnosis of ALS.&#xD;
&#xD;
          -  Healthy controls will also be recruited and will be age- and gender-matched to&#xD;
             patients.&#xD;
&#xD;
          -  Patients able to undergo a brain MRI for approximately an hour.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with other psychiatric or CNS or PNS diseases.&#xD;
&#xD;
          -  Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign&#xD;
             body, or significant claustrophobia that could affect the ability to have an MRI scan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie Garrido Pradalié</last_name>
    <role>Study Director</role>
    <affiliation>Direction Recherche Santé APHM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahram Attarian</last_name>
    <phone>33491386579</phone>
    <email>shahram.attarian@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Olivier Arnaud</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shahram Attarian</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Verschueren</last_name>
      <email>annie.verschueren@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>July 18, 2021</last_update_submitted>
  <last_update_submitted_qc>July 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

